Reactivation of Occult Hepatitis B Virus Infection in Patients with Rheumatic Diseases: Pathogenesis, Risk Assessment and Prevention

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2015 Nov 18

PMID 26573663

Authors

Masaru Kato

Tatsuya Atsumi

Affiliations

Soon will be listed here.

Abstract

Over the past decade, reactivation of occult hepatitis B virus (HBV) infection has garnered much attention from rheumatologists owing to a number of reports which have indicated the potential risk of biologics in causing this previously ignored infectious complication. Hepatitis due to reactivation of occult HBV infection occurs only occasionally but with high mortality upon occurrence, placing us in a clinical dilemma "to address or not to address?" In this review, we discuss how biological and other immunosuppressive therapies increase the risk of developing reactivation of occult HBV infection and attempt to solve this clinical quandary.

References

Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K . Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011; 38(10):2209-14. DOI: 10.3899/jrheum.110289. View

Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z . Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol. 2006; 177(1):739-47. DOI: 10.4049/jimmunol.177.1.739. View

Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N . Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004; 22(3):375-6. View

Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D . Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2012; 72(2):308-10. DOI: 10.1136/annrheumdis-2012-202088. View

van der Molen R, Sprengers D, Binda R, de Jong E, Niesters H, Kusters J . Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004; 40(3):738-46. DOI: 10.1002/hep.20366. View

Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y . Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2010; 21(1):16-23. DOI: 10.1007/s10165-010-0337-z. View

Mori S . Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011; 21(6):621-7. PMC: 3236827. DOI: 10.1007/s10165-011-0458-z. View

Hernandez J, Diloy R, Salat D, del Rio N, Martinez X, Castellvi J . Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica. 2003; 88(6):ECR22. View

Winthrop K, Calabrese L . Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis. 2011; 70(10):1701-3. DOI: 10.1136/annrheumdis-2011-200163. View

10.

Skrabs C, Muller C, Agis H, Mannhalter C, Jager U . Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002; 16(9):1884-6. DOI: 10.1038/sj.leu.2402567. View

11.

Webster A, Brenner M, Prentice H, Griffiths P . Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989; 4(2):207-8. View

12.

Lan J, Chen Y, Hsieh T, Chen Y, Hsieh C, Chen D . Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 70(10):1719-25. DOI: 10.1136/ard.2010.148783. View

13.

Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M . Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007; 13(4):508-9. DOI: 10.1002/ibd.20035. View

14.

Thio C, Mosbruger T, Kaslow R, Karp C, Strathdee S, Vlahov D . Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol. 2004; 78(20):11258-62. PMC: 521829. DOI: 10.1128/JVI.78.20.11258-11262.2004. View

15.

Pei S, Ma M, Wang M, Kuo C, Rau K, Su C . Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012; 91(7):1007-12. DOI: 10.1007/s00277-012-1405-6. View

16.

Charpin C, Guis S, Colson P, Borentain P, Mattei J, Alcaraz P . Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009; 11(6):R179. PMC: 3003507. DOI: 10.1186/ar2868. View

17.

Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S . Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2014; 19(5):470-5. DOI: 10.1111/1756-185X.12359. View

18.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X . Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176):1221-8. PMC: 6309542. DOI: 10.1126/science.1243462. View

19.

Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H . Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011; 46(4):556-64. DOI: 10.1007/s00535-010-0367-5. View

20.

Tur-Kaspa R, Burk R, Shaul Y, Shafritz D . Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A. 1986; 83(6):1627-31. PMC: 323136. DOI: 10.1073/pnas.83.6.1627. View